PRESENTATION

Q4 2025 — Presentation

Q4 2025PDF · 34 pages2.8 MB
Fourth-Quarter 2025
Sales and Earnings
Merck & Co., Inc., Rahway, N.J., USA
February 3, 2026

-- 1 of 34 --

Agenda
2
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Agenda
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session

-- 2 of 34 --

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to
pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements
can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

-- 3 of 34 --

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

-- 4 of 34 --

5
Executing Business Development
Actively pursuing additional science-driven,
value-creating transactions
Launching New Growth Drivers
Expect >20 new growth drivers, almost all of which have
blockbuster potential
Advancing Diverse & Expansive Pipeline
~80 Phase 3 studies ongoing
Transforming our
portfolio with next
wave of innovation
Significant commercial opportunity
Potential commercial opportunity from new growth drivers
increased to >$70B1 by the mid-2030s, reflecting substantial
progress in 2025
1. Non-risk adjusted annual sales by the mid 2030s

-- 5 of 34 --

Delivering revenue growth while investing for the future
6
$16.4B
+5% nominal
+4% ex-exchange
Q4 Worldwide Sales
$2.04
Q4 Non-GAAP
EPS1,3
2025 2026
Guidance Range
Full Year
Sales
$65.0B
(+1% nominal,
+2% ex-exchange)
$65.5B - $67.0B
(+1-3% nominal,
+0-2% ex-exchange)
Full Year
Non-GAAP
EPS1,2
$8.98 	$5.00 - $5.15
1. Merck does not exclude expenses for upfront and milestone payments related to certain collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions
accounted for as asset acquisitions from its non-GAAP results. Fourth quarter of 2025 includes $0.05 per share for such a charge. Full year non-GAAP results for 2025 include $0.20 per share of such items.
Full-year 2026 guidance includes ~$3.65 per share of such a charge. 2. Full year 2025 GAAP EPS $7.28. 3. Fourth quarter of 2025 GAAP EPS $1.19.

-- 6 of 34 --

Remarkable progress across broad and deep pipeline
7
Received FDA approval of KEYTRUDA and
KEYTRUDA QLEX in combination with enfortumab
vedotin based on KEYNOTE-9051
Announced positive topline results for Phase 3
KEYNOTE-B151 and Phase 2b KEYNOTE- 9422
Oncology
Presented Phase 3 results for enlicitide from
CORALreef Lipids and HeFH studies at AHA 2025
Announced positive Phase 2 topline results for
WINREVAIR in CpcPH due to HFpEF
Cardiometabolic
& Respiratory
Announced positive topline results for doravirine +
islatravir in treatment-naïve adults living with HIV
Infectious
Disease
FDA granted Commissioner’s
National Priority Vouchers for
enlicitide and sac-TMT
1. In collaboration with Pfizer and Astellas 2. In collaboration with Moderna, 5 year follow up analysis

-- 7 of 34 --

88
Completed strategic acquisition of Cidara Therapeutics
Strategic fit within portfolio and pipeline
Adds MK-1406, a potential first-in-class, long-acting strain
agnostic antiviral for the prevention of influenza infection in
certain individuals
Significant potential to positively impact public health given
high unmet need
Greater than $5B potential commercial opportunity and driver
of growth entering and through the next decade, creating
shareholder value

-- 8 of 34 --

islatravir + lenacapavir3
NRTTI + capsid inhibitor
MK-1406
zanamivir-Fc conjugate
islatravir + ulonivirine
NRTTI + NNRTI
MK-8527
NRTTI
V181
Tetravalent dengue vaccine
enlicitide decanoate
Oral PCSK9i
doravirine + islatravir
NNRTI + NRTTI
sacituzumab tirumotecan4
TROP2 ADC
ifinatamab deruxtecan5
B7-H3 ADC
zilovertamab vedotin
ROR1 ADC
raludotatug deruxtecan5
CDH6 ADC
nemtabrutinib
BTKi
intismeran autogene6
INT
opevesostat
CYP11A1i
calderasib7
KRAS G12Ci
patritumab deruxtecan5
HER3 ADC
gocatamig5
DLL3 T-cell engager
MK-1045
CD3xCD19 T-cell engager
tulisokibart
TL1A mAb
MK-3000
Wnt agonist
MK-8748
Tie2 agonist/VEGFi
2024 	2025 	2026 	2027 	2028+
bomedemstat
LSD1i
First-in-class potential
Key near-term programs that represent majority of $70B1 of
non-risk adjusted commercial opportunity by the mid-2030s
Transforming our portfolio with more than 20 new growth drivers, almost
all with blockbuster potential
9
Mid-2030s commercial opportunity2 	>$25B1 	~$20B 	~$15B 	>$5B 	>$5B
Oncology Cardiometabolic &
Respiratory Infectious Disease 	Immunology 	Ophthalmology	Therapeutic area
Timing above represents approval date for marketed products or earliest Phase 3 primary completion date according to clinicaltrials.gov for pipeline compounds 1. Excludes KEYTRUDA QLEX 2. Non-risk
adjusted annual sales by the mid 2030s 3. In collaboration with Gilead 4. In collaboration with Kelun 5. In collaboration with Daiichi Sankyo 6. In collaboration with Moderna 7. In collaboration with Taiho and
Astex

-- 9 of 34 --

Data-rich period ahead with multiple Phase 3 readouts across novel
mechanisms
10	10
2026
ISL / LEN1 MK-3000 	tulisokibart
Mechanism of
action
NRTI with
translocation
inhibition / capsid
inhibitor
Wnt agonist 	TL1A mAb
Therapeutic
area HIV 	Ophthalmology 	Immunology
Disease
area Treatment
(oral, QW)
Diabetic macular
edema
Ulcerative
colitis
Phase 3 study
PCD
ISLEND-1 and
ISLEND-2
Apr 2026
BRUNELLO
Sept 2026
(BAROLO Mar 2027)
ATLAS-UC
Aug 2026
2027
sac-TMT2 MK-1406 	I-DXd3
TROP2 ADC zanamivir-Fc
conjugate B7H3 ADC
Oncology Infectious
Disease Oncology
Various tumor
types Influenza Various tumor
types
TroFuse
(16 Phase 3 studies;
PCDs beginning in
2027)
ANCHOR
Jan 2027
IDeate
(3 Phase 3 studies;
PCDs beginning in
2027)
1. In collaboration with Gilead 2. In collaboration with Kelun 3. In collaboration with Daiichi Sankyo

-- 10 of 34 --

Delivering on our purpose for patients and creating long-term value
11
Augmenting pipeline with
strategic business
development
Making significant clinical
advancements
Multiple impactful Phase 3
readouts through 2027
Executing on multiple
product launches
Successful acceleration and
augmentation of pipeline has
yielded >20 potential new
growth drivers

-- 11 of 34 --

Financial Results
and Outlook
Caroline Litchfield
Executive Vice President and
Chief Financial Officer
12

-- 12 of 34 --

Growth driven by strength in Oncology and Animal Health as well as new
product launches
13
$65.0B+1% nominal
+2% ex-exchange
+7% ex-GARDASIL China 2 , ex-exchange
FULL YEAR WORLDWIDE SALES1
Q4 2025 WORLDWIDE SALES1
$16.4B+5% growth
+4% ex-exchange
$14.8B
+6% growth
+4% ex-exchange
Human Health
$1.5B
+8% growth
+6% ex-exchange
Animal Health
1. Worldwide Sales includes Other Revenue 2. There were no sales of GARDASIL in China in 4Q25. Sales of GARDASIL in China were $0.4 billion in 4Q24, $3.5 billion in full year 2024, and $0.2 billion in full
year 2025

-- 13 of 34 --

Oncology: KEYTRUDA continues to benefit patients and drive growth
14
KEYTRUDA family1 sales of $8.4B increased
5%, driven by robust uptake in earlier-stage
cancers and strong demand from metastatic
indications
‒ 	Growth driven by usage in tumors
predominantly affecting women, including those
with certain breast, cervical, and endometrial
cancers
‒ 	Increased use of KEYTRUDA in combination with
enfortumab vedotin in first-line, locally advanced
or metastatic urothelial cancer
‒ 	In the U.S., growth negatively impacted by
~$200M due to timing of purchases
‒ 	KEYTRUDA QLEX sales of $35M in 4Q25
following launch in 3Q25, permanent J-code
expected in April 4Q23 	4Q24 	4Q25
$6.6B
+22%
$8.4B
+5%	$7.8B
+21% 2
Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX 2. ~2 percentage points of negative impact of foreign exchange was due to devaluation
of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market

-- 14 of 34 --

4Q23 	4Q24 	4Q25
Oncology: Continued growth across broad portfolio
15
WELIREG sales grew 37%, driven by demand
in the U.S. and continued launch uptake in
several international markets
Lynparza 1 sales grew 4%, primarily due to
higher demand in several international
markets
Lenvima 2 sales grew 6%, primarily due to
higher sales in the U.S. reflecting higher
demand, partially offset by lower pricing
Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai
4Q23 	4Q24 	4Q25
$365M
+18%
$315M
+8%
$389M
+4%
4Q23 	4Q24 	4Q25
$255M
+14%
$226M
+5%
$272M
+6%
$72M
+78% 	$160M
+123%
$220M
+37%

-- 15 of 34 --

Vaccines & Infectious Disease: Protecting lives globally
4Q23 	4Q24 	4Q25
$1.7B
+40%
4Q23 	4Q24 	4Q25
$1.0B
-35%
Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 3Q25
GARDASIL sales of $1.0B decreased 35%,
driven by lower demand in China and Japan
‒ 	Other international markets grew 8%,
benefitting from the timing of purchases
‒ 	In the U.S., sales grew 7% primarily due to price
CAPVAXIVE 1 sales of $279M driven by
demand from retail pharmacies and non-retail
customers, as well as increased seasonal
immunization activity in the U.S.
ENFLONSIA 2 sales of $21M reflect lower than
expected infant passive immunization rate
and high levels of total RSV mAb inventory in
the market
$279M
+460%
$1.9B
+27% 	$1.6B
-18%
$50M

-- 16 of 34 --

Cardiometabolic & Respiratory: Continuing to drive impact for patients
with successful ongoing launches
WINREVAIR1 sales of $467M driven by
continued growth in new patient starts and
total prescriptions
‒ 	In the U.S., >1,500 new patients prescribed and
>27,000 total prescriptions dispensed
‒ 	Ex-U.S., making progress with approvals and
reimbursement
OHTUVAYRE 2 sales of $178M reflect strong
growth in new patient starts and total
patients treated
‒ 	Growth in breadth and depth of physician
prescribing
4Q23 	4Q24 	4Q25
$1.7B
+40%
4Q23 	4Q24 	4Q25
$178M
Growth rates exclude the impact of foreign exchange 1. Launched in 2Q24 2. Sales following the closing of the acquisition of Verona Pharma on October 7th , 2025
$200M
$467M
+133%

-- 17 of 34 --

Animal Health: Strong growth driven by livestock portfolio
18
Animal Health sales increased 6% to $1.6B
‒ 	Livestock sales grew 9%, driven by higher
demand across all species
‒ 	Companion Animal sales were flat as growth
from new product launches was offset by lower
demand for other products in portfolio due to
lower vet visits
4Q23 	4Q24 	4Q25
$1.3B
+4%
$1.4B
+13% 1
$1.5B
+6%
Growth rates exclude the impact of foreign exchange 1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price
increases, consistent with practice in that market

-- 18 of 34 --

Q4 2025 non-GAAP financial results summary 1
$ in billions, except EPS amounts
19
1. The company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q4 2025 GAAP results include a charge of $0.05
per share related to an agreement with Dr. Falk pursuant to which the Company secured the sole global rights to MK-8690. Q4 2024 includes a charge of $0.23 per share related to the execution of licensing
agreements with LaNova and Hansoh. 3. Q4 2025 GAAP EPS of $1.19.
Q4 2025 	Q4 2024 	Change Change
Ex-FX
Sales 	$16.4 	$15.6 	+5% 	+4%
Non-GAAP Gross Margin 	79.7% 	80.8% 	-1.1 pts 	-0.8 pts
Non-GAAP Operating
Expenses $6.8 	$7.4 	-7% 	-8%
Non-GAAP Tax Rate 	15.4% 	16.2% 	-0.8 pts 	N/A
Non-GAAP EPS2,3 $2.04 	$1.72 	+19% 	+19%

-- 19 of 34 --

2026 financial outlook
20
1. Guidance does not assume any additional significant potential business development transactions
Guidance 	Key Assumptions
Revenue 	$65.5B to $67.0B • 	Assumes ~1 percentage point positive impact from FX
• 	Implies +1 to +3% nominal (+0% to +2% ex-FX)
Non-GAAP
Gross Margin Rate ~82.0%
Non-GAAP
Operating Expenses1 	$35.9B to $36.9B 	• 	Includes ~$9B charge related to acquisition of Cidara
Other (Income) / Expense 	~$1.3B of expense • 	Includes financing costs related to acquisitions of Verona and
Cidara
Tax Rate 	~23.5% to 24.5% 	• 	Includes impact of non-tax deductible charge for Cidara
Shares Outstanding 	~2.48B 	• 	Assumes ~$3B of share repurchases
Non-GAAP EPS1 	$5.00 to $5.15 • 	Includes ~$3.95 negative impact from acquisition of Cidara
• 	Assumes ~$0.10 positive impact from FX

-- 20 of 34 --

Key modeling considerations
21
Expect ~$2.5B Revenue Headwind
• 	Generic competition for JANUVIA
family, BRIDION, and DIFICID
• 	IRA price setting for JANUVIA
• 	Restructured agreement for Koselugo
LAGEVRIO1
• 	Expect lower sales due to softening
demand
1. Available in the U.S. under Emergency Use Authorization

-- 21 of 34 --

Remain committed to balanced capital allocation strategy
Q4 Spend ($ in billions) 1
22
Augmented our pipeline and
portfolio with value-
enhancing business
development while investing
in our pipeline and business
as well as returning cash to
shareholders
1. Reflects quarter spend
2. Reflects R&D excluding Business Development
Capital allocation order of priority
2
$3.2
$1.0 $2.0
$10.6
$1.3
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase

-- 22 of 34 --

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
23

-- 23 of 34 --

Clinical and regulatory advancements across cardiometabolic and
respiratory pipeline
24
Enlicitide 	WINREVAIR
Phase 3 study in adults with or at-risk for atherosclerotic
cardiovascular disease
– Findings presented at AHA
Phase 3 study in adults with heterozygous familial
hypercholesterolemia
‒ Findings presented at AHA
Positive topline results in Phase 3 study of enlicitide
compared to other oral non-statin therapies
– Findings to be presented at ACC
Ongoing CV outcomes study fully enrolled
Phase 3 results support ambition to bring first approved oral
PCSK9i designed to have antibody-like efficacy to broad
population globally
Announced topline results from Phase 2
CADENCE study in adults with CpcPH due to
HFpEF
‒ Detailed results to be presented at ACC
EC approved expanded indication in
combination with other PAH therapies in adults
with PAH WHO functional class II, III and IV
based on the Phase 3 ZENITH study

-- 24 of 34 --

Building on our strong legacy in combatting infectious disease
25
MK-1406
• 	Potential novel first-in-class, long-acting, strain
agnostic antiviral to prevent symptomatic influenza in
certain individuals
• 	Phase 3 ANCHOR study: completed enrollment in
Northern Hemisphere and intend to enroll participants
in Southern Hemisphere
HIV
• 	Announced positive topline results for DOR/ISL in
previously untreated adults with HIV-1 infection
‒ 	First two-drug regimen without an HIV integrase
strand inhibitor to demonstrate non-inferior
efficacy and safety versus
bictegravir/emtricitabine/tenofovir alafenamide

-- 25 of 34 --

Progress across oncology development program
26
Recent approvals
• 	KEYNOTE-9051 : FDA approved KEYTRUDA and
KEYTRUDA QLEX in combination with enfortumab vedotin
for perioperative treatment of cisplatin-ineligible MIBC
• 	KEYTRUDA SC2 : EC approved subcutaneous administration
of KEYTRUDA for all adult indications approved in the EU 	Highlighted progress at ASH 2025
• 	MK-1045 (CD19xCD3 TCE): First presentation of
positive findings from Phase 1b/2 study in adults
with r/r B-cell ALL
• 	Nemtabrutinib (BTKi): Initial positive findings from
exploratory analysis of the BELLWAVE-003 study in
patients with CLL or SLL
• 	Bomedemstat (LSD1i): First-time positive results
from Phase 2 SHORESPAN-004 study in patients
with polycythemia vera resistant or intolerant to
cytoreductive therapy
1. In collaboration with Pfizer and Astellas 2. Approval for new subcutaneous route of administration and new pharmaceutical form of KEYTRUDA, marketed as KEYTRUDA SC in the EU. Subcutaneous injection
contains pembrolizumab and berahyaluronidase alfa 3. In collaboration with Moderna 4. Phase 2b study
• 	KEYNOTE-B151 : Announced study evaluating KEYTRUDA
in combination with enfortumab vedotin met endpoints of
EFS, PCR and OS for perioperative treatment of cisplatin-
eligible MIBC
• 	KEYNOTE-9423,4 : Announced 5-year follow-up results for
intismeran autogene in combination with KEYTRUDA in
high-risk stage III or IV melanoma following complete
resection
‒ 	Phase 3 INTerpath-0013 ongoing and fully enrolled
Announced positive topline results
• 	Initiated KANDLELIT-007 evaluating calderasib
(KRAS G12Ci) in combination with KEYTRUDA QLEX
in 1L KRAS G12C-mutant advanced NSCLC
Recent trial initiations

-- 26 of 34 --

Significant progress across broad pipeline in 2025
27
New Phase 3 trials initiated
21 Delivered on “One Pipeline”
strategy, advancing internal
innovation and discovery and
complementing with the best
external science
Advanced global regulatory approvals
and new indications
Positive Phase 3 trial readouts
18

-- 27 of 34 --

Key upcoming dates and milestones
28
1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX 2. In collaboration with Pfizer and Astellas 3. In collaboration with Gilead
Oncology
KEYTRUDA Family1
• 	KEYNOTE-B96 KEYTRUDA PDUFA date February 20 th
• 	KEYNOTE-B96 KEYTRUDA QLEX PDUFA date April 14 th
• 	Presentation of detailed findings from Phase 3 KEYNOTE-B15 2 in
cisplatin-ineligible patients with MIBC at ASCO-GU
WELIREG
• 	Presentation of detailed findings from Phase 3 LITESPARK-011 and
LITESPARK-022 at ASCO-GU
Cardiometabolic & respiratory
WINREVAIR
• 	Presentation of detailed findings from Phase 2 CADENCE trial in CpcPH
due to HFpEF at ACC
• 	HYPERION PDUFA date September 21st
Enlicitide decanoate
• 	Presentation of detailed findings from Phase 3 CORALreef AddOn trial at
ACC
HIV
Doravirine/Islatravir
• 	PDUFA date April 28th
Islatravir/Lenacapavir3
• 	PCDs in April for Phase 3 ISLEND-1 and ISLEND-2 trials in HIV
treatment
Immunology
Tulisokibart
• 	PCD in May for Phase 2 ATHENA trial in SSc-ILD
• 	PCD in August for Phase 3 ATLAS trial in UC
Ophthalmology
MK-3000
• 	PCD in September for Phase 3 BRUNELLO trial in DME
MK-8748
• 	PCD in April for Phase 2 RIOJA trial in NVAMD, DME, and RVO

-- 28 of 34 --

Q&A
Robert M. Davis
Chairman and Chief Executive Officer
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 29 of 34 --

30
Appendix

-- 30 of 34 --

Q4 2025 GAAP financial results summary
$ in billions, except EPS amounts
31
Q4 2025 	Q4 2024 	Change 	Change Ex-FX
Sales 	$16.4 	$15.6 	+5% 	+4%
Operating Expenses
(SG&A and R&D)1 $6.8 	$7.4 	-9% 	-10%
Tax Rate 	13.4% 	10.2% 	3.2 pts 	N/A
GAAP EPS2 $1.19 	$1.48 	-20% 	-18%
1. Q4 2025 GAAP results include a $150 million charge related to an agreement with Dr. Falk pursuant to which the Company secured the sole global rights to MK-8690. 4Q24 GAAP results include $700
million of charges related to the execution of licensing agreements with LaNova and Hansoh. 2. Q4 2025 GAAP results include a charge of $0.05 per share an agreement with Dr. Falk pursuant to which the
Company secured the sole global rights to MK-8690. Q4 2024 GAAP results include a charge of $0.23 per share related to the execution of licensing agreements with LaNova and Hansoh.

-- 31 of 34 --

2025 GAAP financial results summary
$ in billions, except EPS amounts
32
2025 	2024 	Change 	Change Ex-FX
Sales 	$65.0 	$64.2 	+1% 	+2%
Operating Expenses
(SG&A and R&D)1 $26.5 	$28.8 	-8% 	-8%
Tax Rate 	13.3% 	14.1% 	-0.8 pts 	N/A
GAAP EPS2 $7.28 	$6.74 	+8% 	+10%
1. GAAP results for 2025 and 2024 include charges of $650 million and $3.6 billion, respectively, related to certain licensing agreements and asset acquisitions. 2. GAAP results for 2025 and 2024 include net
charges of $0.20 and $1.28 per share, respectively, related to certain licensing agreements, asset acquisitions, and collaborations.

-- 32 of 34 --

$12.8
$4.1
$8.2
$12.8
$5.1
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Billions
Commitment to the dividend
Capital allocation: Trailing twelve months
33
Well-positioned balance sheet with
capacity to fund additional value-
enhancing business development
opportunities
Capital allocation order of priority
E
Capital investments
2025 to 2029
Over the past 12 months
2
1
$1.84 	$1.88 	$1.92
$2.20 $2.44 $2.60 $2.76 $2.92 	$3.08 $3.24
2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024 	2025
Dollars per share
+2% 	+2% 	+2%
+11%
+15%
+7% +6% +6% 	+5% +5%
Executing upon balanced capital allocation strategy
~$20B
Over 5 years, including more than $12B in the U.S.
1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow

-- 33 of 34 --

MK-1406
Influenza
LAGEVRIO (MK-4482) 1,3
COVID-19 (U.S.)
MK-8527
HIV-1 PrEP
MK-8591A (doravirine + islatravir) (EU)
HIV-1 Infection (EU)
MK-8591D (islatravir + lenacapavir) 1,2
HIV-1 Infection
Broad and innovative pipeline to address significant unmet medical needs
34
As of February 24, 2026
Phase 3
Oncology
MK-1022 (patritumab deruxtecan) 1
Breast
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084 (calderasib) 1
CRC
NSCLC
MK-1308A (quavonlimab +
pembrolizumab)
RCC
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan) 1
Esophageal
Prostate
SCLC
MK-2870 (sacituzumab tirumotecan) 1
Breast
Cervical
Endometrial
Gastric
NSCLC
Ovarian
KEYTRUDA (MK-3475)
SCLC
MK-3543 (bomedemstat)
Myeloproliferative Disorders
MK-5684 (opevesostat)
Prostate
MK-5909 (raludotatug
deruxtecan) 1
Ovarian
LYNPARZA (MK-7339) 1
NSCLC
SCLC
V940 (intismeran autogene) 1
Melanoma
NSCLC
Infectious Disease
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
Cardiometabolic &
Respiratory
MK-0616 (enlicitide decanoate)
Hypercholesterolemia
MK-30004
Diabetic Macular Edema
Ophthalmology
Phase 2
MK-3120
Bladder
KEYTRUDA (MK-3475)
Prostate
KEYTRUDA QLEX (MK-3475A)
Hematological Malignancies (U.S.)
MK-5684 (opevesostat)
Breast
Endometrial
Ovarian
MK-5909 (raludotatug
deruxtecan) 1
Bladder
Cervical
Endometrial
Gastric
NSCLC
RCC
SCLC
MK-6070 (gocatamig) 1
SCLC
WELIREG (MK-6482)
Breast
V940 (intismeran autogene) 1
Bladder
RCC
MK-1022 (patritumab deruxtecan) 1
Biliary
Bladder
Cervical
Endometrial
Esophageal
Gastric
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreatic
Prostate
MK-1084 (calderasib) 1
Solid Tumors
MK-2400 (ifinatamab deruxtecan) 1
Biliary
Bladder
Breast
Cervical
Endometrial
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreatic
MK-2870 (sacituzumab
tirumotecan) 1
Biliary
Bladder
Esophageal
Neoplasm Malignant
Pancreatic
Oncology
Infectious Disease
MK-8591B (islatravir +
ulonivirine)
HIV-1 Infection
MK-5475
PH-COPD
MK-5884A (ensifentrine +
glycopyrrolate)
COPD
MK-6024 (efinopegdutide)
MASH
MK-7262
Atherosclerosis
WINREVAIR (MK-7962)
Pulmonary Hypertension due to
Left Heart Disease
Cardiometabolic &
Respiratory
MK-7240 (tulisokibart)
Axial Spondyloarthritis
Hidradenitis Suppurativa
Rheumatoid Arthritis
Systemic Sclerosis
Immunology
MK-1167
Alzheimer’s Disease
MK-2214
Alzheimer’s Disease
Neuroscience
Under regulatory review
Oncology
KEYTRUDA (MK-3475)
Breast (U.S.)
MIBC (EU, JPN)
Ovarian (EU, JPN)
KEYTRUDA QLEX (MK-3475A)
Breast (U.S.)
WELIREG (MK-6482)
Clear Cell RCC Following Nephrectomy (U.S.) 5
Previously Treated Advanced RCC (U.S.) 1
MK-8748
Eye Disorders
Ophthalmology
V181
Dengue Fever Virus
Vaccines
Phase 3	Phase 2
Infectious Disease
ENFLONSIA (MK-1654)
Respiratory Syncytial Virus (EU, JPN)
MK-8591A (doravirine + islatravir)
HIV-1 Infection (U.S., JPN)
Cardiometabolic &
Respiratory
WINREVAIR (MK-7962)
Pulmonary arterial hypertension (U.S.)
1. Being developed in a collaboration 2. On partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization 4. Program is in Phase 2/3 study 5. Under review for combination use with
KEYTRUDA or KEYTRUDA QLEX.

-- 34 of 34 --